Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Mar 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):268–277. doi: 10.1097/01.qai.0000435600.65845.31

Table 1. HIV-specific T cell immune responses in the 38 infants who received the full set of ALVAC vaccinations and all placebo recipients.

	Birth			Week 10			Month 24
	Placebo (%)	ALVAC (%)	P^a	Placebo (%)	ALVAC (%)	P^a	Placebo (%)	ALVAC (%)	P^a
CD4^b ICS	0/11 (0)	0/33 (0)	--	2/9 (22.2)	2/38 (5.3)	0.16	1/9 (11.1)	6/36 (16.7)	1.00
CD4^c CFSE	0/11 (0)	2/34 (5.9)	1.00	0/7 (0)	9/31 (29.0)	0.16	0/7 (0)	0/30 (0)	--
CD8^b ICS	0/11 (0)	0/33 (0)	--	1/9 (11.1)	1/38 (2.6)	0.35	0/9 (0)	5/36 (13.9)	0.57
CD8^c CFSE	0/11 (0)	1/34 (2.9)	1.00	0/7 (0.0)	3/31 (9.7)	1.00	0/7 (0)	0/30 (0)	-

^a

P-values from two-sided Fisher's Exact test

^b

Effector assay: Intracellular cytokine and/or CD107

^c

CFSE proliferation